title: The endothelin pathway: a protective or detrimental target of bardoxolone methyl on cardiac function in patients with advanced chronic kidney disease?
abstract: Bardoxolone methyl has been reported to cause detrimental cardiovascular events in the terminated BEACON Phase III human clinical trial via modulation of the renal endothelin pathway. However, the effects of bardoxolone methyl administration on the endothelin pathway in the heart are unknown. Our purpose in this perspective is to highlight the distinctive opposing roles of the renal and heart endothelin pathway in cardiac function. Furthermore, we address the need for further investigation in order to determine if bardoxolone methyl has a protective role in cardiac function through the suppression of the endothelin pathway in the heart.
authors.affiliation: School of Medicine, and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia.
authors.forename: Danielle
authors.initials: D
authors.lastname: Camer
authors.forename: Xu-Feng
authors.initials: XF
authors.lastname: Huang
mesh_terms: D001794:Blood Pressure; D002319:Cardiovascular System / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D057239:Early Termination of Clinical Trials; D016232:Endothelins / Q000378:metabolism*; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007668:Kidney / Q000378:metabolism* / Q000502:physiology; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D009828:Oleanolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D016232:Endothelins; D009828:Oleanolic Acid; C445068:bardoxolone methyl